Group 1 - The overall performance of the innovative drug sector is weak, with most stocks declining and some leading products experiencing significant drops [1] - The current risk appetite in the capital market is suppressed, which is reflected in the lack of positive feedback from recent TACO transactions [1] - Despite the short-term challenges, the long-term investment value of innovative drugs remains optimistic, supported by favorable fundamentals and upcoming industry conferences [1] Group 2 - The innovative drug sector has undeniable global competitiveness in certain areas, with ongoing business development (BD) efforts expected to yield positive results in the future [1] - Many companies in the sector have strong fundamentals, with sufficient cash flow and advancing pipelines, indicating a stable growth outlook [1] - The current capital market cycle is challenging, with risk assets experiencing valuation compression, but historical patterns suggest potential for rapid rebounds in high-risk assets [1][2]
长城基金梁福睿：创新药静待风偏转好或行业利好刺激
Xin Lang Ji Jin·2025-10-15 08:04